Profile: MediciNova Inc (MNOV.O)

MNOV.O on Consolidated Issue listed on NASDAQ Global Market

10 Jul 2020
Change (% chg)

$0.04 (+0.73%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Company Address

MediciNova Inc

4275 Executive Sq Ste 300
LA JOLLA   CA   92037-8408
P: +1858.3731500
F: +1858.4040048

Company Web Links